Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass

Journal of Clinical Monitoring and Computing

Volumn 17, Issue 5, 2002, Pages 287-292

  Welsby, Ian J ^a   McDonnell, Elizabeth ^b   El Moalem, Habib ^a   Stafford Smith, Mark ^a   Toffaletti, John G ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Angioplasty; Blood coagulation tests mt methods ; Cardiopulmonary bypass; Equipment design; Heparin ad administration dosage ; Human; Percutaneous coronary; Transluminal; Whole blood coagulation time.

Indexed keywords

CARDIOVASCULAR SYSTEM; COAGULATION; PATIENT MONITORING; PULMONARY DISEASES;

CLOTTING;

BIOMEDICAL ENGINEERING;

ANTITHROMBOCYTIC AGENT; HEPARIN; PROTAMINE;

ADULT; ANALYZER; ANTICOAGULATION; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE CALCULATION; HEART DISEASE; HEART SURGERY; HEPARINIZATION; HUMAN; HYPOTHESIS; MEDICAL TECHNOLOGY; MODEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; HEPARIN; HUMANS; MONITORING, PHYSIOLOGIC; REPRODUCIBILITY OF RESULTS; WHOLE BLOOD COAGULATION TIME;

EID: 0347928631     PISSN: 13871307     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021298103264     Document Type: Article

References (18)

1. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation: I. J Thorac Cardiovasc Surg 1975; 69 (5): 674-684
2. Hattersley PC. Activated coagulation time of whole blood. JAMA 1966; 196: 436-444
3. Niinikoski J, Laato M, Laaksonen V, Jalonen J, Inberg MV. Use of activated clotting time to monitor anticoagulation during cardiac surgery. Scand J Thorac Cardiovasc Surg 1984; 18 (1): 57-61
4. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980; 79 (1): 97-102
5. Preiss DU, Schmidt-Bleibtreu H, Berguson P, Metz G. Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique. Klin Wochenschr 1985; 63 (6): 252-256
6. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg 1977; 24 (2): 170-173
7. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. J Cardiothorac Vasc Anesth 1999; 13 (4 Suppl 1): 18-29; discussion 36-37
8. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation: II. J Thorac Cardiovasc Surg 1975; 69 (5): 685-689
9. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978; 26 (3): 231-240
10. Reich DL, Zhal K, Perucho MH, Thys DM. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monit 1992; 8 (1): 33-36
11. Avendano A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23 (4): 907-910
12. Leyvi G, Shore-Lesserson L, Harrington D, Vela-Cantos F, Hossain S. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation. Anesth Analg 2001; 92 (3): 578-583
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1 (8476): 307-310
14. Little RC, Milliken GA, Stroup WW, Wolfinger RD. (SAS Institute Inc., Cary, NC.). SAS System for Mixed Models 1996.
15. Zucker ML, Jobes C, Siegel M, Jobes D, LaDuca FM. Activated clotting time (ACT) testing: Analysis of reproducibility. J Extra-Corpor Technol 1999; 31 (3): 130-134
16. Shirota K, Watanabe T, Takagi Y, Ohara Y, Usui A, Yasuura K. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. Artif Organs 2000; 24 (1): 49-56
17. Despotis GJ, Joist JH, Hogue CW, Jr. et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110 (1): 46-54
18. Despotis GJ, Filos KS, Zoys TN, Hogue CW, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82 (1): 13-21